AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights:
Frontier IP Group PLC's portfolio company, The Vaccine Group (TVG), has been awarded a grant exceeding £400,000 from Innovate UK to develop vaccines for cattle using a novel herpesvirus-based antigen delivery platform.
The company’s portfolio firm, Deakin Bio-Hybrid Materials, successfully raised £693,000 in an oversubscribed funding round to advance the development of low-energy processes for producing bio-based materials.
Frontier IP emphasizes collaboration with industry partners to ensure that its technology aligns with real-world needs, strengthening the commercial viability of its portfolio companies.
Frontier IP Group PLC, (LSE:FIPP) a company specializing in the commercialization of intellectual property, has recently announced significant advancements within its portfolio. The Vaccine Group (TVG), a key portfolio company, has received a grant of over £400,000 from Innovate UK in collaboration with the Animal and Plant Health Agency (APHA). This funding is designated for the development of vaccines targeting critical diseases in cattle, specifically bovine respiratory syncytial virus (BRSV) and lumpy skin disease. CEO Jeremy Salt highlighted the commercial implications of these diseases, noting that BRSV affects nearly two million calves annually in the UK, leading to substantial financial losses in the industry.
In addition to TVG’s success, another portfolio company, Deakin Bio-Hybrid Materials, has successfully secured £693,000 through an oversubscribed funding round. This capital will support the development of innovative low-energy processes to produce bio-based materials, positioning the company as a leader in sustainable alternatives to traditional ceramics.
Frontier IP Group continues to focus on its mission to bridge the gap between science, finance, and industry. The company involves relevant industry partners early in the development process, ensuring that its technologies meet genuine market demands. This approach not only enhances the commercial potential of its portfolio companies but also underscores the importance of collaboration in the advancement of novel technologies.
Overall, Frontier IP Group’s commitment to fostering innovation and supporting its portfolio companies through strategic partnerships and funding is indicative of its ongoing efforts to drive progress in the scientific and commercial sectors. With TVG's recent grant and Deakin Bio-Hybrid's funding success, the company is poised for continued growth and impact in the market.
